ICD-11 5A40: Intermediate Hyperglycaemia (Primary Care Guide)

Key Takeaways

ICD-11 5A40 (prediabetes) codes intermediate hyperglycaemia with subcodes: 5A40.0 (IFG), 5A40.1 (IGT), 5A40.Z (unspecified)

Replaces ICD-10 R73.0 (WHO) / R73.01-R73.02 (ICD-10-CM) with distinct clinical subcodes

Requires documented glucose testing and cardiovascular risk assessment

Primary care documentation must include lifestyle intervention plans

Excludes diabetes (5A10, 5A11), elevated blood glucose (MA18.0), and neonatal hyperglycaemia (KB60.3)

ICD-11 5A40: Intermediate Hyperglycaemia (Prediabetes) — Definition and Clinical Context

ICD-11 code 5A40 represents intermediate hyperglycaemia—clinically synonymous with prediabetes—a metabolic state between normal glucose regulation and type 2 diabetes mellitus. This diagnostic classification captures patients with impaired fasting glucose (5A40.0), impaired glucose tolerance (5A40.1), or elevated HbA1c levels that do not meet diabetes thresholds. The World Health Organization introduced 5A40 as part of the ICD-11 endocrine coding structure to standardise prediabetes reporting across healthcare systems, with “prediabetes” listed as an official index term for this code.

Primary care practitioners code intermediate hyperglycaemia when laboratory results confirm glucose dysregulation without meeting full diabetes criteria. The condition affects over 1.1 billion adults globally according to International Diabetes Federation 2024 data (635 million with impaired glucose tolerance and 488 million with impaired fasting glucose). Digital patient intake forms streamline the collection of metabolic risk factors during initial assessments. Early identification through accurate coding enables preventive interventions that reduce progression to type 2 diabetes by up to 58% in high-risk populations.

Clinical documentation requirements for 5A40 extend beyond simple glucose values. Practices must record testing methodology, whether fasting plasma glucose, oral glucose tolerance test, or HbA1c measurement. WHO guidance specifies that intermediate hyperglycaemia exists when HbA1c falls between 39 and 47 mmol/mol (5.7 to 6.4% in DCCT units). WHO ICD-10 used a single code R73.0 (Abnormal glucose) for both impaired fasting glucose and impaired glucose tolerance, while ICD-10-CM (used in the US) separated these into R73.01 (IFG) and R73.02 (IGT). ICD-11 improves on both by providing distinct subcodes under 5A40: 5A40.0 for impaired fasting glucose and 5A40.1 for impaired glucose tolerance.

ICD-11 5A40 Subcodes for Prediabetes Classification

ICD-11 5A40 Exclusion Codes

ICD-11 explicitly excludes several conditions from the 5A40 classification. Coders must verify that the patient’s presentation does not fall under these excluded categories before assigning 5A40:

• MA18.0 — Elevated blood glucose level (isolated lab finding without clinical prediabetes diagnosis)
• KB60.3 — Neonatal hyperglycaemia (hyperglycaemia in the newborn period)
• 5A10 — Type 1 diabetes mellitus
• 5A11 — Type 2 diabetes mellitus
• 5A13 — Other specified diabetes mellitus
• 5A14 — Unspecified diabetes mellitus

If a patient’s glucose values meet diabetes diagnostic thresholds (fasting glucose ≥7.0 mmol/L, 2-hour OGTT ≥11.1 mmol/L, or HbA1c ≥48 mmol/mol), assign the appropriate diabetes code (5A10–5A14) rather than 5A40. The exclusion of MA18.0 is particularly relevant: an incidental finding of mildly elevated blood glucose during acute illness does not warrant a 5A40 prediabetes diagnosis without confirmatory testing.

Diagnostic Criteria for ICD-11 5A40 Intermediate Hyperglycaemia (Prediabetes)

The diagnostic threshold for intermediate hyperglycaemia requires meeting at least one of three laboratory criteria. WHO defines impaired fasting glucose (5A40.0) as fasting plasma glucose between 6.1 and 6.9 mmol/L (110 to 125 mg/dL), while the American Diabetes Association uses a lower threshold of 5.6 mmol/L (100 mg/dL). Practices should clarify which threshold they follow, as this affects screening sensitivity. Two-hour post-load glucose during an oral glucose tolerance test between 7.8 and 11.0 mmol/L (140 to 199 mg/dL) confirms impaired glucose tolerance (5A40.1). HbA1c values from 39 to 47 mmol/mol (5.7 to 6.4%) represent the third diagnostic pathway, typically coded as 5A40.Z when neither IFG nor IGT has been specifically tested.

These criteria align with WHO and ADA diagnostic standards, though the IFG threshold difference (detailed above) means screening sensitivity varies by guideline. WHO’s ICD-11 browser provides the official classification structure for endocrine disorders. Laboratories must use standardised testing methods calibrated to DCCT reference standards for HbA1c or plasma glucose analysers meeting ISO 15197 accuracy requirements. Point-of-care devices require validation against laboratory reference methods before use in diagnostic coding.

Primary care documentation should specify which diagnostic pathway confirmed intermediate hyperglycaemia. A patient with HbA1c 42 mmol/mol (6.0%) but normal fasting glucose still meets 5A40 criteria. Testing must occur on separate days to exclude transient hyperglycaemia from acute illness or stress. Laboratory management systems track repeat testing intervals and flag results requiring clinical follow-up.

Laboratory Testing Protocols

Fasting plasma glucose testing requires an eight-hour fast with water permitted. Patients should avoid unusual physical activity or dietary changes in the preceding three days. Timing affects results significantly. A morning venous sample processed within 30 minutes provides the most reliable data. Some practices mistakenly code intermediate hyperglycaemia based on capillary glucose readings, which lack diagnostic accuracy for formal classification.

Oral glucose tolerance tests involve administering 75 grams of glucose solution after overnight fasting. Plasma glucose measurements occur at baseline and two hours post-ingestion. The patient must remain seated without smoking during the test period. OGTT provides the most sensitive detection of glucose intolerance but requires more practice resources than HbA1c testing. Many GP clinics now prefer HbA1c screening due to convenience and pre-analytical stability.

Clinical Documentation Requirements for 5A40

Accurate ICD-11 5A40 intermediate hyperglycaemia coding demands comprehensive clinical notes that justify the diagnosis. Electronic medical records must capture the specific glucose measurement, testing date, and fasting status. Documentation should include cardiovascular risk factors such as hypertension, dyslipidaemia, family history of diabetes, and body mass index. These contextual details support care planning and demonstrate medical necessity for interventions.

NICE guidelines recommend assessing 10-year cardiovascular risk using QRISK or similar validated tools for all patients with intermediate hyperglycaemia. This risk stratification influences treatment intensity and follow-up frequency. Patient portals enable individuals to access their test results and personalised risk assessments between appointments. Primary care teams should document lifestyle counselling discussions, including dietary advice, physical activity goals, and weight management targets.

Beyond the subcodes (5A40.0, 5A40.1, 5A40.Y, 5A40.Z), ICD-11 5A40 supports post-coordination in some contexts to specify aetiology or comorbidities. A patient with intermediate hyperglycaemia secondary to corticosteroid use needs additional coding for drug-induced hyperglycaemia. Similarly, gestational diabetes that resolves postpartum but leaves persistent intermediate hyperglycaemia requires dual classification. AI-powered clinical documentation tools help practitioners identify relevant co-codes from consultation transcripts.

Structured Data Entry Standards

Electronic health record templates for intermediate hyperglycaemia should include mandatory fields for test type, test result, test date, and clinical interpretation. Drop-down menus prevent free-text variations that complicate data extraction for quality audits. Structured entries enable automated clinical decision support, such as flagging patients due for annual HbA1c screening or those who have progressed to diabetes thresholds.

Best practice templates incorporate SNOMED CT codes alongside ICD-11 classifications. SNOMED 714628002 maps to intermediate hyperglycaemia and enables interoperability with pathology laboratories and hospital systems. GP practices participating in NHS Digital reporting or QOF achievement monitoring need both coding systems operational. Centralised patient records maintain coding consistency across multi-site practices.

Primary Care Management Protocols for ICD-11 5A40

Patients diagnosed with intermediate hyperglycaemia require structured lifestyle intervention programmes as first-line management. The Diabetes Prevention Programme research demonstrated that intensive lifestyle modification reduces diabetes incidence more effectively than metformin in this population. Primary care protocols should specify dietary referral, physical activity prescription, and weight reduction targets where BMI exceeds 25 kg/m².

Dietary advice centres on reducing refined carbohydrate intake, increasing fibre consumption to at least 30 grams daily, and limiting saturated fat to less than 10% of total energy. Mediterranean dietary patterns show consistent benefits in metabolic studies. Physical activity goals target 150 minutes of moderate-intensity exercise weekly, such as brisk walking, cycling, or swimming. Automated care protocols deliver structured advice through patient apps between appointments.

Pharmacological intervention with metformin becomes appropriate for patients with multiple risk factors who fail to achieve lifestyle targets. NICE recommends considering metformin for those with BMI over 35 kg/m², age under 40 with strong family history, or previous gestational diabetes. Prescribing decisions require documentation in the clinical record linked to the 5A40 code. Annual HbA1c monitoring identifies progression to type 2 diabetes, triggering reclassification from 5A40 to ICD-11 5A11 (Type 2 diabetes mellitus). Note: intermediate hyperglycaemia is always coded as 5A40 (with subcodes 5A40.0 or 5A40.1 where applicable)—do not use any other code for this condition.

Follow-Up Scheduling and Care Pathways

Intermediate hyperglycaemia patients need annual HbA1c testing at minimum, with six-month intervals for high-risk individuals. Clinical systems should automatically generate recall reminders when test dates approach. Cardiovascular risk assessment updates occur every three years unless new risk factors emerge. Blood pressure measurement and lipid profile testing follow standard cardiovascular prevention schedules.

Some practices establish group education sessions for newly diagnosed intermediate hyperglycaemia patients. These structured programmes cover diet, exercise, glucose monitoring, and diabetes warning signs. Group formats improve cost-effectiveness compared to individual consultations while maintaining clinical outcomes. Class management features support scheduling and attendance tracking for group interventions.

Streamline ICD-11 Coding Workflows

See how Pabau's clinical documentation tools support accurate diagnostic coding, automated care pathways, and comprehensive patient record management for primary care practices.

Book a demo

Transition from ICD-10 to ICD-11 5A40 Coding

The shift from ICD-10 to ICD-11 intermediate hyperglycaemia coding introduces meaningful subcode structure. WHO ICD-10 used a single code R73.0 (Abnormal glucose) without distinguishing IFG from IGT, while ICD-10-CM (US) separated these into R73.01 and R73.02. ICD-11 5A40 improves on both approaches: 5A40.0 specifically captures impaired fasting glucose, 5A40.1 captures impaired glucose tolerance, and 5A40.Z covers unspecified cases—combining the simplicity of a parent code with the granularity of distinct subcodes.

This consolidation affects data continuity for practices tracking prediabetes prevalence over time. Historical ICD-10 coded records require mapping to 5A40 equivalents during system migrations. Note that R73.01 and R73.02 are ICD-10-CM (US) codes—UK practices using WHO ICD-10 will be mapping from R73.0, which covered both IFG and IGT without distinction. NHS Digital coding guidance provides UK-specific transition resources. UK practices moving to ICD-11 should run dual coding during transitional periods to maintain audit trail integrity.

Some electronic health record systems lack native ICD-11 support, requiring practices to operate crosswalk tables between ICD-10 and ICD-11 codes. These mapping tables introduce potential classification errors if not regularly validated. Clinical coders should verify that automated conversions correctly translate R73.0 codes to the appropriate 5A40 subcode (5A40.0 for IFG, 5A40.1 for IGT, or 5A40.Z when unspecified) rather than defaulting to unspecified hyperglycaemia categories. GP practice management systems with built-in ICD-11 libraries eliminate manual mapping errors.

Implementation Considerations for Primary Care

Practice teams need training on ICD-11 structure and coding conventions before go-live. The hierarchical organisation differs from ICD-10, with more granular parent-child relationships. Understanding post-coordination syntax becomes essential for complex cases requiring multiple classification elements. WHO provides free online training modules through the ICD-11 reference guide portal.

Testing EHR system functionality with sample intermediate hyperglycaemia cases identifies configuration issues before full deployment. Validation should confirm that 5A40 codes trigger appropriate clinical decision support rules, such as diabetes prevention programme referral pathways or annual screening reminders. Report writers may need updates to aggregate ICD-11 classifications for quality improvement dashboards.

Country-Specific Coding Variations and Reimbursement

Healthcare systems worldwide adopt ICD-11 at different rates, creating temporary international coding inconsistencies. The United Kingdom plans full NHS Digital transition to ICD-11 by 2026, while other nations maintain hybrid approaches using ICD-10 for billing and ICD-11 for epidemiological reporting. Private healthcare providers may implement ICD-11 earlier to align with international insurance standards.

Reimbursement structures influence coding granularity for intermediate hyperglycaemia. Countries with bundled payment models for diabetes prevention may not require detailed 5A40 post-coordination. Fee-for-service systems need precise documentation to justify lifestyle counselling or dietetic referrals. Claims management platforms validate coding accuracy against payer-specific requirements before submission.

UK private medical insurers increasingly recognise intermediate hyperglycaemia as a reimbursable condition for preventive consultations and diagnostic testing. BUPA and AXA PPP accept 5A40 coding for diabetes prevention programme referrals when medical necessity documentation meets policy criteria. NHS primary care contracts incorporate intermediate hyperglycaemia management within Quality and Outcomes Framework diabetes domains, though specific 5A40 coding may not trigger direct payment.

Documentation for Private Healthcare Billing

Private healthcare claims require detailed clinical justification for intermediate hyperglycaemia consultations. Insurers expect documentation of specific glucose values, testing methodology, and cardiovascular risk assessment. Treatment plans must demonstrate medical necessity for any interventions billed separately from the consultation code. Letters of medical necessity should reference ICD-11 5A40 explicitly and quote relevant WHO diagnostic thresholds.

Some insurers pre-authorise diabetes prevention programmes for patients with documented intermediate hyperglycaemia and additional risk factors. Pre-authorisation requests need supporting laboratory reports, BMI calculations, and family history documentation. Patient record systems that generate pre-authorisation packets automatically reduce administrative workload and claim rejection rates.

Quality Improvement and Audit Considerations

Clinical audit programmes track intermediate hyperglycaemia detection rates, lifestyle intervention uptake, and progression to type 2 diabetes. Accurate ICD-11 5A40 coding enables population health analytics that identify gaps in screening coverage or follow-up. Practices should audit the proportion of eligible patients receiving HbA1c testing within recommended intervals and those with documented lifestyle advice.

National diabetes prevention programmes rely on coded data to measure intervention effectiveness and cost-effectiveness. The NHS Diabetes Prevention Programme uses ICD-11 classifications to stratify referral patterns and outcome metrics. Quality improvement cycles should review coding accuracy by sampling patient records and comparing documented glucose values against assigned diagnostic codes. Discrepancies often reveal training gaps or EHR template deficiencies.

Benchmark comparisons between practices require standardised coding approaches. Some clinics under-code intermediate hyperglycaemia by documenting findings in free text without formal ICD-11 classification. This practice distorts prevalence estimates and prevents patients from accessing diabetes prevention services. Clinical dashboards highlight coding completeness rates alongside clinical quality indicators.

Expert Picks

Need comprehensive metabolic assessment tools? Heart Attack Troponin Levels Chart provides cardiovascular biomarker interpretation guidance for high-risk patients with intermediate hyperglycaemia.

Looking to optimise preventive care workflows? Wellness Clinic Software explores features supporting diabetes prevention programmes, lifestyle intervention tracking, and patient engagement strategies.

Seeking structured documentation frameworks? SAFER Clinical Notes demonstrates evidence-based documentation practices that improve coding accuracy and reduce medico-legal risk in chronic disease management.

Conclusion

ICD-11 code 5A40 provides a structured classification for intermediate hyperglycaemia (prediabetes) with clinically meaningful subcodes: 5A40.0 for impaired fasting glucose, 5A40.1 for impaired glucose tolerance, and 5A40.Z for unspecified cases. Primary care practitioners must understand the diagnostic thresholds (noting the WHO vs ADA difference for IFG), exclusion codes, documentation requirements, and management protocols associated with this classification. Accurate coding enables population health tracking, quality improvement initiatives, and appropriate reimbursement for preventive interventions.

The transition from ICD-10 to ICD-11 requires investment in training, system configuration, and workflow redesign. Practices that implement robust coding practices position themselves to deliver evidence-based diabetes prevention care while meeting audit and reimbursement standards. Regular quality audits ensure coding accuracy and identify opportunities to improve intermediate hyperglycaemia detection rates across patient populations.

Frequently Asked Questions